Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults

被引:310
作者
French, N
Gray, K
Watera, C
Nakiyingi, J
Lugada, E
Moore, M
Lalloo, D
Whitworth, JAG
Gilks, CF
机构
[1] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England
[2] Med Res Programme, DFID, Uganda Virus Res Inst, Entebbe, Uganda
关键词
Cryptococcus; HIV; Africa; epidemiology; clinical presentation; cryptococcal antigen;
D O I
10.1097/00002030-200205030-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: Despite the recognition of Cryptococcus neoformans as a major cause of meningitis in HIV-infected adults in sub-Saharan Africa, little is known about the relative importance of this potentially preventable infection as a cause of mortality and suffering in HIV-infected adults in this region. Design: A cohort study of 1372 HIV-1-infected adults, enrolled and followed up between October 1995 and January 1999 at two community clinics in Entebbe, Uganda. Methods: Systematic and standardized assessment of illness. episodes to describe cryptococcal disease and death rates. Results: Cryptococcal disease was diagnosed in 77 individuals (rate 40.4/1000 person-years) and was associated with 17% of all deaths (77 out of 444) in the cohort. Risk of infection was strongly associated with CD4 T cell counts < 200 x 10(6) cells/l (75 patients) and World Health Organization (WHO) clinical stage 3 and 4 (68 patients). Meningism was present infrequently on presentation (18%). Clinical findings had limited discriminatory diagnostic value. Serum cryptococcal antigen testing was the most sensitive and robust diagnostic test. Cryptococcal antigenaemia preceded symptoms by a median of 22 days (> 100 days in 11 % of patients). Survival following diagnosis was poor (median survival 26 days; range 0-138). Conclusions: Cryptococcal infection is an important contributor to mortality and suffering in HIV-infected Ugandans. Improvements in access to effective therapy of established disease are necessary. In addition, prevention strategies, in particular chemoprophylaxis, should be evaluated while awaiting the outcome of initiatives to make antiretroviral therapy more widely available. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:1031 / 1038
页数:8
相关论文
共 29 条
[1]   Fever and human immunodeficiency virus infection as sentinels for emerging mycobacterial and fungal bloodstream infections in hospitalized patients ≥15 years old, Bangkok [J].
Archibald, LK ;
McDonald, LC ;
Rheanpumikankit, S ;
Tansuphaswadikul, S ;
Chaovanich, A ;
Eampokalap, B ;
Banerjee, SN ;
Reller, LB ;
Jarvis, WR .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (01) :87-92
[2]   Fatal Mycobacterium tuberculosis bloodstream infections in febrile hospitalized adults in Dar es Salaam, Tanzania [J].
Archibald, LK ;
den Dulk, MO ;
Pallangyo, KJ ;
Reller, LB .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (02) :290-296
[3]   Trends in bloodstream infections among human immunodeficiency virus-infected adults admitted to a hospital in Nairobi, Kenya, during the last decade [J].
Arthur, G ;
Nduba, VN ;
Kariuki, SM ;
Kimari, J ;
Bhatt, SM ;
Gilks, CF .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (02) :248-256
[4]  
Bergemann A, 1996, QJM-MON J ASSOC PHYS, V89, P499
[5]   AIDS-associated Cryptococcal meningitis in Rwanda (1983-1992): Epidemiologic and diagnostic features [J].
Bogaerts, J ;
Rouvroy, D ;
Taelman, H ;
Kagame, A ;
Aziz, MA ;
Swinne, D ;
Verhaegen, J .
JOURNAL OF INFECTION, 1999, 39 (01) :32-37
[6]  
CAHN P, 1993, AIDS, V7, P711
[7]   ANTIBODIES ELICITED BY A CRYPTOCOCCUS-NEOFORMANS TETANUS TOXOID CONJUGATE VACCINE HAVE THE SAME SPECIFICITY AS THOSE ELICITED IN INFECTION [J].
CASADEVALL, A ;
MUKHERJEE, J ;
DEVI, SJN ;
SCHNEERSON, R ;
ROBBINS, JB ;
SCHARFF, MD .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (06) :1086-1093
[8]  
CASADEVALL A, 2001, CRYPTOCOCCUS NEOFORM
[9]   Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand [J].
Chen, S ;
Sorrell, T ;
Nimmo, G ;
Speed, B ;
Currie, B ;
Ellis, D ;
Marriott, D ;
Pfeiffer, T ;
Parr, D ;
Byth, K .
CLINICAL INFECTIOUS DISEASES, 2000, 31 (02) :499-508
[10]  
COX DR, 1972, J R STAT SOC B, V34, P187